Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify Company / Ticker to Get the Summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
DBV Technologies
DBVTCurrent price
7.98 USD
+0.07 USD (+0.88%)
Last closed
7.44 USD
Company
www.dbv-technologies.com
ISIN
US23306J1016
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Capitalization
218 144 480 USD
Yield for 12 month
+20.73 %
1Y
3Y
5Y
10Y
15Y
DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France. Address: Bâtiment IRO, Châtillon, France, 92320
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
23.68 USDP/E ratio
–Dividend Yield
–Current Year
–
Last Year
+15 728 000 USD
Current Quarter
–
Last Quarter
–
Current Year
–
Last Year
+15 728 000 USD
Current Quarter
–
Last Quarter
–
Key Figures DBVT
1 year
3 years
5 years
10 years
EBITDA
-79 693 000 USD
Operating Margin TTM
Price to Earnings
–
Return On Assets TTM
-58.61 %
PEG Ratio
–
Return On Equity TTM
-135.96 %
Wall Street Target Price
23.68 USD
Revenue TTM
4 151 000 USD
Book Value
0.27 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
-94.20 %
Dividend Yield
–
Gross Profit TTM
4 151 000 USD
Earnings per share
-5.85 USD
Diluted Eps TTM
-5.85 USD
Most Recent Quarter
IV 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics DBVT
Max Ratio
>10 - expected double digit dividend yield on cost over 10Y >5 - expected 5-9 dividend yield on cost over 10Y <5 - expected <5 dividend yield on cost over 10Y MaxRatio is an estimated 10Y dividend yield on cost calculated by combining the current dividend yield with the 5-year & 10-year average dividend growth rate, projected over the next 10 years discounted based on current Financial Score. It provides a projected outlook on future dividend returns.
–5Y Dividend Growth
–Consecutive Years
–5Y Average Payout Ratio
–Dividend History DBVT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Ex Dividend Date
–
Dividend CAGR 3Y
–
Dividend CAGR 5Y
–
Dividend CAGR 10Y
–
Consecutive Years
Consistent Years
Continuous Dividends
Forward Annual Dividend Yield
–
Forward Annual Dividend
– USD
Last Split Factor
1:2
Payout Ratio
–
Last Split Date
07.06.2024
Stock Valuation DBVT
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
–
Price Sales TTM
52.55
Enterprise Value EBITDA
-2.07
Price Book MRQ
7.97
Financials DBVT
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators DBVT
For 52 weeks
2.20 USD
8.50 USD
50 Day MA
5.25 USD
Shares Short Prior Month
340 543
200 Day MA
2.60 USD
Short Ratio
0.54
Shares Short
561 856
Short Percent
0.33 %
BeatStart